Viewing Study NCT05681195


Ignite Creation Date: 2025-12-24 @ 1:19 PM
Ignite Modification Date: 2026-02-01 @ 7:06 PM
Study NCT ID: NCT05681195
Status: RECRUITING
Last Update Posted: 2025-05-20
First Post: 2022-12-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Sponsor: Baptist Health South Florida
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Central Nervous System Lymphoma View
None Secondary Central Nervous System Lymphoma View
None Relapsed Cancer View
None Refractory Cancer View
Keywords: